Merck & Co., Inc. (Animal Health Division)
Merck Animal Health
Merck Animal Health (MSD Animal Health outside North America) is the animal health powerhouse division of pharmaceutical giant Merck & Co., leveraging the parent company's $65.01 billion total revenue and $7+ billion annual R&D engine. Headquartered in Rahway, New Jersey, USA. With Animal Health revenue of USD 6.4 billion (2025), the division operates manufacturing in 50+ countries, supported by 75,000 parent-company employees. Merck Animal Health is currently executing the industry's most ambitious biologics capacity buildout, committing $895M to a 200,000 sq ft Kansas De Soto "Center of Excellence" and $185M to an Austria Krems multi-line vaccine facility.
Strengths:
• Parent Company Scientific Depth: Access to Merck & Co.'s $7B+ annual R&D spend and deep biologics expertise, creating unmatched scientific spillover into veterinary applications
• Blockbuster Parasiticide Portfolio: Bravecto series generated $11B in 2025 sales, establishing category leadership in long-duration parasiticides with 12-week protection duration
• Unprecedented Manufacturing Expansion: $895M Kansas De Soto and $185M Austria Krems concurrent facility expansions signal a long-term strategic commitment to owning the entire biologics value chain
• Diversified Revenue Base: Spanning companion animals, livestock, and newly acquired aquaculture business (post-$1.29B Elanco aqua acquisition), providing multi-segment cyclical resilience
• Regulatory Excellence: Deep institutional knowledge of FDA, EMA, and USDA approval pathways accelerates time-to-market for new animal drug applications
Weaknesses:
• Divisional Dependency: As a non-independent entity within Merck & Co., strategic capital allocation must compete with the human pharmaceutical portfolio's priorities
• Companion Animal Revenue Underweight: At $24.58B vs $38.96B livestock, the pet segment remains proportionally smaller relative to pure-play competitor Zoetis
• Clinic Visit Sensitivity: Certain quarters in 2025 saw companion animal sales stagnate as macroeconomic pressures reduced veterinary clinic visit frequencyRead MoreShow Less
Strengths:
• Parent Company Scientific Depth: Access to Merck & Co.'s $7B+ annual R&D spend and deep biologics expertise, creating unmatched scientific spillover into veterinary applications
• Blockbuster Parasiticide Portfolio: Bravecto series generated $11B in 2025 sales, establishing category leadership in long-duration parasiticides with 12-week protection duration
• Unprecedented Manufacturing Expansion: $895M Kansas De Soto and $185M Austria Krems concurrent facility expansions signal a long-term strategic commitment to owning the entire biologics value chain
• Diversified Revenue Base: Spanning companion animals, livestock, and newly acquired aquaculture business (post-$1.29B Elanco aqua acquisition), providing multi-segment cyclical resilience
• Regulatory Excellence: Deep institutional knowledge of FDA, EMA, and USDA approval pathways accelerates time-to-market for new animal drug applications
Weaknesses:
• Divisional Dependency: As a non-independent entity within Merck & Co., strategic capital allocation must compete with the human pharmaceutical portfolio's priorities
• Companion Animal Revenue Underweight: At $24.58B vs $38.96B livestock, the pet segment remains proportionally smaller relative to pure-play competitor Zoetis
• Clinic Visit Sensitivity: Certain quarters in 2025 saw companion animal sales stagnate as macroeconomic pressures reduced veterinary clinic visit frequency
Listed market data
MRK · NYSE · weeklyHistory →- Market cap
- $360 B
- Share price
- USD 145.95
- 1Y change
- +69.0%
- Recent change
- -1.3%
- Since first close
- ×109
- Revenue (TTM)
- USD$6.4 B (Animal Health segment, 2025)
10-22 → 10-23
from 1970-01
Financial history
Full market history- 2026-10USD 145.27$360 B-0.0%
- 2026-09USD 145.31$360 B-1.7%
- 2026-08USD 147.76$366 B+13.5%
- 2026-07USD 130.20$323 B+1.3%
- 2026-06USD 128.50$319 B+8.2%
- 2026-05USD 118.72$294 B+8.7%
- 2026-04USD 109.18$271 B-9.2%
- 2026-03USD 120.29$298 B-2.9%
- 2026-02USD 123.82$307 B+12.3%
- 2026-01USD 110.27$273 B+4.8%
- 2025-12USD 105.26$261 B+0.4%
- 2025-11USD 104.83$260 B—
In the press
All coverage →5 latest headlines2- AVMF announces US$400k Merck scholarship funding - Vet Timeswww.vettimes.com2026-10-19
- AbbVie vs. Merck: Which Pharma Stock Offers Better Value?finance.yahoo.com2026-10-16
- Merck Stock: Watch This Price, Prepare To Profit From This Tradefinance.yahoo.com2026-10-16
- Merck’s Rally Reflects Renewed Confidence, but Has the Market Priced in Too Much?finance.yahoo.com2026-10-16
- How Has Merck's Story Changed?trefis.com2026-10-15
In Europe, it acquired and is converting the former Baxter facility in Krems, Austria approximately €185 million investment into a multi-line animal vaccine production plant. With over 50 country-level direct operations and products reaching 150+ nations, Merck Animal Health maintains complete control over its core biologic manufacturing processes while benefiting from the parent company's $7+ billion annual R&D spend.
• Parasiticides: Bravecto series 12-week duration
• Vaccines: Nobivac / Vanguard
• Anti-infectives: MOMETAMAX SINGLE otitis treatment
• Dermatology and specialty therapeutics
• Aquaculture health post-Elanco acquisition
Quick Facts
Headquarters
Rahway, New Jersey, United States
Founded
1940
Employees
75,000 (parent Merck & Co.)
Revenue
USD$6.4 B (Animal Health segment, 2025)
Market cap
$360 B
Factories
Global manufacturing in 50+ countries; $895M Kansas De Soto expansion; $185M Austria Krems facility
Presence
Products in 150+ countries, direct offices in 50+ countries
Listing
NYSE: MRK (parent)
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck & Co., Inc.· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NYSE: MRK (parent) , Merck Animal Health Official Website
SEC EDGAR — Merck & Co. Filings
Wikipedia — Merck & Co.